Research programme: biosimilars - ARA Healthcare

Drug Profile

Research programme: biosimilars - ARA Healthcare

Alternative Names: ARABS 1; ARABS 2; ARABS 3; ARABS 4; ARABS 5; ARABS 6; ARABS 7; ARABS 8

Latest Information Update: 11 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ARA Healthcare
  • Class Enzymes; Interferons; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Rheumatoid arthritis
  • Research Cancer; Crohn's disease; Hairy cell leukaemia; Hepatitis C; Inflammation; Multiple sclerosis

Most Recent Events

  • 18 May 2015 Early research in Cancer in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
  • 18 May 2015 Early research in Crohn's disease in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
  • 18 May 2015 Early research in Hairy cell leukaemia in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top